The U.S. Food and Drug Administration has approved the first gene therapy ever cleared to treat inherited deafness, offering children and adults born with a specific genetic form of hearing loss a one-time treatment that addresses the root cause of their condition. The therapy’s maker, Regeneron, has said it will be provided free to patients in the U.S., though out-of-pocket administration costs may still apply depending on a patient’s doctor and insurance.
At a glance
- Gene therapy approval: The FDA cleared Otarmeni on April 23, 2026 C.E. to treat hearing loss caused by mutations in the OTOF gene, marking the first approval of its kind for an inherited hearing condition.
- OTOF gene mutations: The therapy targets a defect in both copies of the OTOF gene, which disrupts production of otoferlin — a protein inner ear cells need to translate vibrations into brain signals.
- Trial results: In a 20-person clinical trial, 16 participants showed improved hearing within six months and one more showed improvement within a year, with all who responded reaching hearing levels that typically do not require cochlear implantation.
What the therapy does
Otarmeni uses harmless viruses to carry working copies of the OTOF gene directly into cells of the inner ear. The OTOF gene codes for otoferlin, a protein that acts as a messenger between the hair cells of the cochlea and the auditory nerve. When a person inherits two defective copies of the gene — one from each parent — that communication breaks down entirely, producing severe-to-profound hearing loss from birth.
The treatment is given once. In the clinical trial, some participants improved to the point that they could hear whispers. All participants who responded reached a hearing threshold that does not typically require a cochlear implant — the surgically implanted device many people with this form of deafness currently use to partially restore hearing. Cochlear implants, while effective, do not replicate natural hearing and require ongoing maintenance.
The approval covers both children and adults with OTOF-related hearing loss, provided they have no history of cochlear implant use in the ear to be treated — because implant surgery damages inner ear structures that the gene therapy needs intact. Patients who have one cochlear implant may still be eligible to receive Otarmeni in the other ear. Candidates must also have functional outer hair cells, which amplify sound vibrations in the cochlea.
Speed and significance
The FDA reviewed Otarmeni through its “fast track” process, which is reserved for therapies that fill a serious unmet medical need with no existing treatments addressing the underlying cause. From the first patient dosed in 2023 C.E. to approval in 2026 C.E. took less than three years — unusually quick for a novel biological therapy.
Zheng-Yi Chen, an associate scientist at the Eaton-Peabody Laboratories at Mass Eye and Ear and an associate professor at Harvard Medical School, called the data from the trial a convincing demonstration of both safety and efficacy. “The FDA approval of this gene therapy is a landmark moment for the field and, most importantly, for patients,” Chen told Live Science. He added that the speed of approval “underscores both the robust clinical results and the urgent, unmet medical need for children with OTOF-mediated congenital hearing loss.”
Dr. A. Eliot Shearer, an otolaryngologist at Boston Children’s Hospital and associate professor at Harvard Medical School who ran the trial, described what he witnessed firsthand: participants responding to their mother’s voice, dancing to music, and engaging with the world around them. Those moments, he said in a Regeneron statement, are now possible for more children born with this specific form of hearing loss.
Who it reaches — and what remains unresolved
OTOF-related hearing loss affects roughly 50 newborns per year in the U.S., making it a rare condition even within the broader population of people born deaf or hard of hearing. The therapy applies only to this specific genetic subtype, leaving the vast majority of people with inherited hearing loss — caused by mutations in other genes or by non-genetic factors — without a comparable option.
An international trial testing Otarmeni is still ongoing and actively recruiting children under 18 in the U.S., the U.K., Spain, Germany, and Japan. Longer-term data on how durable the hearing improvements are over years or decades have not yet been reported. Researchers and clinicians, including Chen, hope this approval will accelerate development of similar gene therapies for other forms of genetic hearing loss — of which there are many.
The cost structure is also worth watching. While Regeneron has committed to providing the therapy itself at no charge to patients, the administration costs — which could include surgical facility fees, specialist visits, and insurance-dependent expenses — remain variable and are not yet fully defined. For a therapy requiring specialized surgical delivery into the inner ear, those costs could be significant for some families.
Still, for the small but real group of children born each year with two defective copies of the OTOF gene, the arrival of a federally approved, cause-addressing treatment marks a genuine shift. The therapy’s maker now moves into the next phase: getting the treatment to the patients who need it.
Read more
For more on this story, see: Live Science
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
